Electromed (ELMD) Competitors

Bioventus (NYSE:BVS) and Electromed (NYSE:ELMD) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, community ranking, dividends, profitability, risk, valuation, media sentiment and analyst recommendations.

Do analysts recommend BVS or ELMD?

Bioventus presently has a consensus price target of $15.00, suggesting a potential upside of 53.53%. Electromed has a consensus price target of $38.00, suggesting a potential upside of 52.79%. Given Bioventus' higher probable upside, equities analysts clearly believe Bioventus is more favorable than Electromed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bioventus	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67
Electromed	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	4.00

Does the media refer more to BVS or ELMD?

In the previous week, Bioventus had 4 more articles in the media than Electromed. MarketBeat recorded 6 mentions for Bioventus and 2 mentions for Electromed. Bioventus' average media sentiment score of 0.58 beat Electromed's score of 0.30 indicating that Bioventus is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bioventus	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Electromed	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Do institutionals and insiders believe in BVS or ELMD?

62.9% of Bioventus shares are held by institutional investors. Comparatively, 40.8% of Electromed shares are held by institutional investors. 32.9% of Bioventus shares are held by company insiders. Comparatively, 14.0% of Electromed shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Which has higher earnings and valuation, BVS or ELMD?

Electromed has lower revenue, but higher earnings than Bioventus. Bioventus is trading at a lower price-to-earnings ratio than Electromed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bioventus	$573.28M	1.38	-$156.23M	-$0.51	-19.16
Electromed	$59.63M	3.57	$5.15M	$0.75	33.16

Is BVS or ELMD more profitable?

Electromed has a net margin of 11.34% compared to Bioventus' net margin of -7.11%. Electromed's return on equity of 15.71% beat Bioventus' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bioventus	-7.11%	15.61%	4.01%
Electromed	11.34%	15.71%	13.37%

Which has more risk & volatility, BVS or ELMD?

Bioventus has a beta of 0.86, indicating that its stock price is 14% less volatile than the S&P 500. Comparatively, Electromed has a beta of 0.41, indicating that its stock price is 59% less volatile than the S&P 500.

Does the MarketBeat Community prefer BVS or ELMD?

Bioventus received 10 more outperform votes than Electromed when rated by MarketBeat users. However, 91.30% of users gave Electromed an outperform vote while only 63.27% of users gave Bioventus an outperform vote.

Company	Underperform	Outperform
Bioventus	Outperform Votes 31 63.27%	Underperform Votes 18 36.73%
Electromed	Outperform Votes 21 91.30%	Underperform Votes 2 8.70%

Summary

Electromed beats Bioventus on 10 of the 19 factors compared between the two stocks.